Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest Immunosuppressants Stories

2013-12-07 23:02:25

MarketReportsOnline.com offers “Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)” in its store. Key drug manufacturers of the global rheumatoid arthritis market like Abbvie Inc. (Humira), Amgen Inc. (Enbrel), Johnson & Johnson (Remicade), Roche Holdings AG (Actemra) are profiled in the report. Dallas, TX (PRWEB) December 07, 2013 The report titled "Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)" provides an in-depth...

2013-12-05 08:27:49

Seventy-Two Percent of Surveyed Dermatologists Expect to Prescribe Apremilast if the Drug is Placed on a Preferred Tier, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that--following the approval of Janssen Biotech's Stelara for psoriatic arthritis--about one-third of surveyed dermatologists expect to at least...

2013-12-04 08:30:55

However, Patient Access to Biologics is Set to Improve as Brazil Evolves to Nationwide Coverage of RA Biologics in 2014, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the National Health System (SUS) covers all the biologics available for rheumatoid arthritis (RA) in Brazil. Covered biologics are provided...

2013-11-30 23:03:24

MarketReportsOnline.com offers “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)” research that analyzes the global market sizing and growth of multiple sclerosis in terms of revenue, number of patients and sales of effective drugs. Dallas, Texas (PRWEB) November 30, 2013 The report titled "Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)" provide an insight into the market dynamics and various trends and opportunities associated...

2013-11-27 15:06:57

Among children and adolescents with Crohn disease not responding to treatment, use of the drug thalidomide resulted in improved clinical remission after 8 weeks of treatment compared with placebo, according to a study appearing in the November 27 issue of JAMA. As many as 1.2 million people in Europe and more than half a million in the United States are estimated to have Crohn disease, a chronic inflammatory disease involving the digestive system. Its incidence is increasing globally....

2013-11-25 08:28:08

Advanced Stent Technology to Launch Immediately in the United States NATICK, Mass., Nov. 25, 2013 /PRNewswire/ -- Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES). The technology is available immediately...

2013-11-22 00:20:42

Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints PARIS and TARRYTOWN, N.Y., Nov. 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the SARIL-RA-MOBILITY Phase 3 clinical trial in adult patients with active rheumatoid arthritis (RA) who were inadequate responders to methotrexate (MTX) therapy, sarilumab (the first fully-human anti-IL-6R monoclonal antibody) treatment in...

2013-11-20 08:28:20

MISSISSAUGA, ON, Nov. 20, 2013 /CNW/ - Genzyme, a Sanofi company, announced today that Health Canada has approved AUBAGIO® (teriflunomide) 14 mg as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. "There are many patients who simply cannot tolerate injections and have had no simple, effective, once daily oral medication until now,"...

2013-11-14 23:04:03

Reportbuyer.com just published a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules. London (PRWEB) November 14, 2013 The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen’s Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera’s launch in Europe. Genzyme have taken advantage of...

2013-11-14 12:59:30

Groundbreaking research to be featured at 2013 AAPS Annual Meeting and Exposition A novel combination anti-psoriasis therapy has potential for superior and longer-lasting therapeutic effects than current topical treatments by targeting genetic abnormalities in deeper layers of the skin. This research is being presented at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Antonio, Nov....